A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
Clinical trial NCT02555306 · COMPLETED
Trial details
- NCT number
- NCT02555306
- Sponsor
- Santen Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-16
- Primary completion
- 2017-08-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.